Taken together, our results suggest that β-lapachone–targeting HIF-1α have a therapeutic potential as an anti-angiogenic drug for variable ischaemia-induced vaso-proliferative retinopathies, especially for ROP. This evidence concerns the gene HIF1A and retinopathy of prematurity.